Since the controversy over the effectiveness of Vytorin erupted, health insurers haven’t rushed to downgrade their coverage of the cholesterol drug. But Cigna now says it’s suspending its requirements for certain patients to try Vytorin, jointly sold by Merck and Schering-Plough, before trying alternatives, such as Pfizer’s Lipitor and AstraZeneca’s Crestor.
Vytorin remains on the second [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment